Psilocybin

Generic Name: Psilocybin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₂O_₄P

CAS Number: 520-52-5

Unique Ingredient Identifier: 2RV7212BP0

Background: Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Stress Experience Following Psilocybin

Phase 2

Not yet recruiting

Conditions: Assessing the Importance of Cortisol in Facilitating Positive Outcomes Induced by Psilocybin in Healthy Participants

Interventions: Drug: Psilocybin 25 mg
Drug: Psilocybin 1 mg
Drug: Placebo
Drug: Metyrapone 750 mg

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: University of Calgary

Target Recruit Count: 36

Registration Number: NCT06768944

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

Early Phase 1

Not yet recruiting

Conditions: IBS - Irritable Bowel Syndrome

Interventions: Drug: Psilocybin 25 mg
Behavioral: Psychotherapy Treatment Session
Drug: Niacin 100 mg

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT06760533

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

Phase 1

Recruiting

Conditions: Bipolar Depression

Interventions: Drug: Psilocybin
Device: Functional MRI

First Posted Date: 2024-07-17

Last Posted Date: 2024-10-18

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT06506019

Locations: 🇨🇦
Toronto Western Hospital - University Health Network, Toronto, Ontario, Canada

Mechanistic Studies of Psilocybin in Headache Disorders

Early Phase 1

Recruiting

Conditions: Migraine

Interventions: Drug: Psilocybin
Drug: Placebo

First Posted Date: 2024-06-18

Last Posted Date: 2025-01-09

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT06464367

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Phase 1

Recruiting

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: Psilocybin

First Posted Date: 2024-05-28

Last Posted Date: 2025-01-09

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 20

Registration Number: NCT06430541

Locations: 🇺🇸
Outpatient CTRC, Aurora, Colorado, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Advanced Cancer
Stage IV Melanoma
Endocrine Cancer
Stage IV Solid Tumor Cancer
Stage IV Sarcoma of Bone
Stage IV Lymphoma

Interventions: Drug: Psilocybin

First Posted Date: 2024-05-16

Last Posted Date: 2024-07-16

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 15

Registration Number: NCT06416085

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Phase 3

Recruiting

Conditions: Treatment Resistant Depression
Refractory Depression

Interventions: Drug: psilocybin

First Posted Date: 2024-03-12

Last Posted Date: 2024-07-23

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 20

Registration Number: NCT06303739

Locations: 🇺🇸
UNC Chapel Hill Medical Center, Chapel Hill, North Carolina, United States

Psilocybin for Treatment-Resistant Depression

Phase 2

Recruiting

Conditions: Treatment Resistant Depression
Major Depressive Disorder
Anhedonia

Interventions: Drug: Psilocybin 25mg
Drug: Placebo (active placebo)

First Posted Date: 2024-01-30

Last Posted Date: 2024-11-01

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT06230757

Locations: 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Phase 2

Recruiting

Conditions: Borderline Personality Disorder
Major Depressive Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-08

Lead Sponsor: University of Chicago

Target Recruit Count: 10

Registration Number: NCT05399498

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

Phase 1

Recruiting

Conditions: Perception Disorders

Interventions: Drug: Psilocybin

First Posted Date: 2022-03-03

Last Posted Date: 2025-01-01

Lead Sponsor: University of California, Berkeley

Target Recruit Count: 80

Registration Number: NCT05265546

Locations: 🇺🇸
University of California, Berkeley, Berkeley, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy